Influenza A Virus, H1N1 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Influenza A Virus, H1N1 Subtype Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.
Key Targets in the Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market
In the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market the key targets are Hemagglutinin, Exo Alpha Sialidase, Hemagglutinin HA, Toll Like Receptor 2, Hemagglutinin 1, Matrix Protein 2, Opioid Receptor, Polymerase Basic Protein 2, Toll Like Receptor 4, and 2019 Novel Corona Virus Spike Glycoprotein.
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market
Exo Alpha Sialidase Inhibitor has the highest number of pipeline products followed by Hemagglutinin Inhibitor, Opioid Receptor Antagonist, Polymerase Basic Protein 2 Inhibitor, Bacterial Cell Wall Disruptor, Envelope Protein M Inhibitor, G Protein Coupled Receptor Agonist, Glucocorticoid Receptor Agonist, Influenza M2 Proton Channel Blocker, and Interleukin 12 Receptor Agonist.
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market are intramuscular, nasal, oral, intravenous, inhalational, parenteral, subcutaneous, transdermal, intradermal, and topical. Intramuscular has the maximum number of pipeline products.
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market
The key molecule types in the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market are small molecule, subunit vaccine, inactivated vaccine, live attenuated vaccine, vaccine, synthetic peptide, mRNA vaccine, recombinant vector vaccine, fusion protein, and antibody.
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market
The major companies in the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market are Adimmune Corp, Blue Water Vaccines Inc, Cocrystal Pharma Inc, CSL Ltd, Moderna Inc, NanoViricides Inc, Statera Biopharma Inc, Vironova Medical AB, AbbVie Inc, Abzyme Therapeutics LLC, Alla Chem LLC, and Allergy Therapeutics Plc.
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Influenza A Virus, H1N1 Subtype Infections Pipeline Drugs Market Overview
| Key Targets | Hemagglutinin, Exo Alpha Sialidase, Hemagglutinin HA, Toll Like Receptor 2, Hemagglutinin 1, Matrix Protein 2, Opioid Receptor, Polymerase Basic Protein 2, Toll Like Receptor 4, and 2019 Novel corona Virus Spike Glycoprotein |
| Key Mechanisms of action | Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Opioid Receptor Antagonist, Polymerase Basic Protein 2 Inhibitor, Bacterial Cell Wall Disruptor, Envelope Protein M Inhibitor, G Protein Coupled Receptor Agonist, Glucocorticoid Receptor Agonist, Influenza M2 Proton Channel Blocker, and Interleukin 12 Receptor Agonist |
| Key Routes of Administration | Intramuscular, Nasal, Oral, Intravenous, Inhalational, Parenteral, Subcutaneous, Transdermal, Intradermal, and Topical Inhalational, Intramuscular, Oral, Nasal, Intravenous, and Transdermal |
| Key Molecule Types | Small Molecule, Subunit Vaccine, Inactivated Vaccine, Live Attenuated Vaccine, Vaccine, Synthetic Peptide, mRNA Vaccine, Recombinant Vector Vaccine, Fusion Protein, and Antibody |
| Major Companies | Adimmune Corp, Blue Water Vaccines Inc, Cocrystal Pharma Inc, CSL Ltd, Moderna Inc, NanoViricides Inc, Statera Biopharma Inc, Vironova Medical AB, AbbVie Inc, Abzyme Therapeutics LLC, Alla Chem LLC, and Allergy Therapeutics Plc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
In the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market the key targets are Hemagglutinin, Exo Alpha Sialidase, Hemagglutinin HA, Toll Like Receptor 2, Hemagglutinin 1, Matrix Protein 2, Opioid Receptor, Polymerase Basic Protein 2, Toll Like Receptor 4, and 2019 Novel corona Virus Spike Glycoprotein.
In the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market the key mechanisms of action are Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Opioid Receptor Antagonist, Polymerase Basic Protein 2 Inhibitor, Bacterial Cell Wall Disruptor, Envelope Protein M Inhibitor, G Protein Coupled Receptor Agonist, Glucocorticoid Receptor Agonist, Influenza M2 Proton Channel Blocker, and Interleukin 12 Receptor Agonist.
The key routes of administration in the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market are Intramuscular, Nasal, Oral, Intravenous, Inhalational, Parenteral, Subcutaneous, Transdermal, Intradermal, and Topical.
The key molecule types in the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market are Small Molecule, Subunit Vaccine, Inactivated Vaccine, Live Attenuated Vaccine, Vaccine, Synthetic Peptide, mRNA Vaccine, Recombinant Vector Vaccine, Fusion Protein, and Antibody.
In the Influenza A Virus, H1N1 Subtype Infections pipeline drugs market the major companies are Adimmune Corp, Blue Water Vaccines Inc, Cocrystal Pharma Inc, CSL Ltd, Moderna Inc, NanoViricides Inc, Statera Biopharma Inc, Vironova Medical AB, AbbVie Inc, Abzyme Therapeutics LLC, Alla Chem LLC, and Allergy Therapeutics Plc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Infectious Disease reports